Stock Events

Stock Events

Xenon Pharmaceuticals 

€49.4
0
+€0.2+0.41% Today

Statistics

Day High
49.4
Day Low
49
52W High
53
52W Low
25
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-1.11
-1.08
-1.04
-1.01
Expected EPS
-1.00657179822
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XP0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Xenon's focus on neurological disorders.
Biogen
BIIB
Mkt Cap27.62B
Biogen competes in the neurological disorder space, particularly in developing therapies for diseases like multiple sclerosis and Alzheimer's, overlapping with Xenon's target market.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes competes with Xenon in developing treatments for central nervous system (CNS) disorders, including schizophrenia and bipolar disorder.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals is a competitor due to its focus on RNA-targeted drug discovery for neurological diseases, a similar area of interest as Xenon.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
ACADIA Pharmaceuticals targets the CNS disorder market, with a focus on psychosis and schizophrenia treatments, areas that overlap with Xenon's research interests.
AMGEN
AMGN
Mkt Cap178B
Amgen, with its broad focus on biotechnological therapies for various conditions, competes indirectly with Xenon through its investments in neuroscience and neurodegenerative diseases.
PTC Therapeutics
PTCT
Mkt Cap5.43B
PTC Therapeutics operates in the space of rare diseases, including neurological disorders, making it a competitor to Xenon's specialized focus.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat genetic disorders, competing with Xenon's approach to drug development.

About

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Show more...
CEO
Mr. Thomas Patrick Kelly J.D.
Employees
316
Country
Canada
ISIN
CA98420N1050

Listings

STU
DE
XP0.STU
MU
DE
XP0.MU
XNAS
US
XENE
F
DE
XP0.F

0 Comments

Share your thoughts

FAQ

What is Xenon Pharmaceuticals stock price today?▼
The current price of XP0.STU is €49.4 EUR — it has increased by +0.41% in the past 24 hours. Watch Xenon Pharmaceuticals stock price performance more closely on the chart.
What is Xenon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xenon Pharmaceuticals stocks are traded under the ticker XP0.STU.
Is Xenon Pharmaceuticals stock price growing?▼
XP0.STU stock has risen by +6.03% compared to the previous week, the month change is a +0.41% rise, over the last year Xenon Pharmaceuticals has showed a +60.78% increase.
When is the next Xenon Pharmaceuticals earnings date?▼
Xenon Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Xenon Pharmaceuticals earnings last quarter?▼
XP0.STU earnings for the last quarter are -1.11 EUR per share, whereas the estimation was -1.01 EUR resulting in a -9.94% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Xenon Pharmaceuticals have?▼
As of May 06, 2026, the company has 316 employees.
In which sector is Xenon Pharmaceuticals located?▼
Xenon Pharmaceuticals operates in the Health & Wellness sector.
When did Xenon Pharmaceuticals complete a stock split?▼
Xenon Pharmaceuticals has not had any recent stock splits.
Where is Xenon Pharmaceuticals headquartered?▼
Xenon Pharmaceuticals is headquartered in Burnaby, Canada.